Flavonol synthase gene MsFLS13 regulates saline-alkali stress tolerance in alfalfa

Alfalfa(Medicago sativa L.) is one of the most extensively grown leguminous forage worldwide.Environmental saline-alkali stress significantly influences the growth,development,and yield of alfalfa,posing a threat to its agricultural production.However,little is known about the potential mechanisms by which alfalfa responds to saline-alkali stress.Here,we investigated these mechanisms by cloning a saline-alkali-induced flavonol synthase gene(Ms FLS13) from alfalfa,which was previously reported to be significantly upregulated under saline-alkali stress,and examining its function in the saline-alkali response.Overexpression of Ms FLS13 in alfalfa promoted plant tolerance to saline-alkali stress by enhancing flavonol accumulation,antioxidant capacity,osmotic balance,and photosynthetic efficiency.Conversely,Ms FLS13 inhibition using RNA interference reduced flavonol synthase activity and inhibited hairy root growth under saline-alkali stress.Yeast one-hybrid and dual-luciferase reporter assays indicated that the R2R3-MYB Ms MYB12 transcription factor activates Ms FLS13 expression by binding to the MBS motif in the Ms FLS13 promoter.Further analysis revealed that abscisic acid mediates the salinealkali stress response partially by inducing Ms MYB12 and Ms FLS13 expression,which consequently increases flavonol levels and maintains antioxidant homeostasis in alfalfa.Collectively,our findings highlight the crucial role of Ms FLS13 in alfalfa in response to saline-alkali stress and provide a novel genetic resource for creating saline-alkali-resistant alfalfa through genetic engineering.

愈风宁心制剂临床应用现状及治疗心脑血管疾病有效性和安全性的Meta分析

目的:分析愈风宁心(yu feng ning xin,YFNX)制剂临床应用现状,并系统评价YFNX制剂治疗心脑血管疾病的有效性和安全性。方法:计算机检索中国知网、万方数据库、中国生物医学文献数据库及PubMed、Embase、The Cochrane Library数据库,搜集关于YFNX制剂的临床研究相关文献,检索时限均为建库至2021年02月,提取相关资料分析YFNX制剂的临床应用现状。选取该药治疗心脑血管疾病的临床随机对照试验和病例对照研究,由2位评价员独立筛选文献、提取资料并评价纳入文献的方法学质量,采用RevMan 5.3软件进行Meta分析考察YFNX制剂治疗心脑血管疾病有效性和安全性。结果:共纳入29篇涉及YFNX制剂的临床研究,剂型为滴丸、片剂、胶囊、冲剂,用于治疗冠心病、高血压、神经性头痛等多种临床病证。纳入13个研究系统评价YFNX制剂在冠心病、高血压、神经性头痛的有效性和安全性,共1162例病例,其中YFNX制剂组582例,西药组580例。Meta分析结果显示,与单纯西药组相比,YFNX制剂+西药/YFNX制剂治疗可明显提高冠心病、高血压、神经性头痛的临床疗效,改善冠心病的心电图,减少心绞痛及头痛的发作次数,缩短心绞痛及头痛的持续时间,降低神经性头痛的头痛评分,差异具有统计学意义(P<0.05)。结论:YFNX制剂对冠心病、高血压、神经性头痛有较好的临床疗效,且不良反应少。